Compound Guide• 7 min read
GLOW Peptide Blend: GHK-Cu + BPC-157 + TB-500 Research Overview
GLOW is the trade name for a three-peptide research blend combining GHK-Cu, BPC-157, and TB-500 in a single lyophilized vial. It is one of the most-purchased research blends in the US peptide market because the three compounds cover complementary tissue-repair pathways.
What's in a GLOW vial
The most common GLOW format is 70 mg total peptide: 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500. Some suppliers also stock a 50 mg version (35 / 10 / 5 mg). Zerilyx ships the 70 mg ratio as standard.
Why these three compounds are blended
Each component contributes a distinct, well-characterized signal in tissue-repair research:
- GHK-Cu — dermal remodeling, antioxidant gene modulation, collagen and glycosaminoglycan synthesis
- BPC-157 — angiogenesis via VEGFR2 and BACH1, tendon/ligament migration, GI protection
- TB-500 (a synthetic fragment of thymosin β-4) — actin-binding, cell migration, and wound-bed organization
Research format and reconstitution
GLOW ships as a single white lyophilized cake. The standard reconstitution in research protocols is 2 mL bacteriostatic water, yielding 35 mg/mL total peptide (25 mg/mL GHK-Cu, 5 mg/mL BPC-157, 5 mg/mL TB-500).
Because all three peptides are typically dosed in the low-mg range, a 70 mg vial supports multi-week study designs without re-mixing.
Where blends fit in research
Pre-mixed blends are popular in laboratory settings where the experimental design specifically calls for combined signaling — for example, soft-tissue repair models that benefit from simultaneous angiogenic, anti-inflammatory, and matrix-remodeling activity.
For studies isolating a single mechanism, single-compound vials are preferred so that effects can be cleanly attributed.
FAQ
Is GLOW the same as KLOW or Wolverine?
No. KLOW typically adds KPV (an anti-inflammatory tripeptide). Wolverine usually combines BPC-157 + TB-500 only. GLOW is specifically the GHK-Cu + BPC-157 + TB-500 trio.
Why is GHK-Cu the largest component?
GHK-Cu acts at lower per-mass potency than BPC-157 or TB-500 in published models, so the ratio reflects practical dosing equivalence rather than relative importance.